Cargando…
2219: Amyotrophic lateral sclerosis, stem cells and TALENted technology
OBJECTIVES/SPECIFIC AIMS: The current treatment for amyotrophic lateral sclerosis (ALS) includes systemic delivery of neurotrophic factors (NTFs). Although this approach may seem theoretically sound, NTF efficacy within the central nervous system (CNS) is largely limited by the blood-brain barrier....
Autores principales: | Kurani, Shaheen, Madigan, Nicolas, Clark, Karl, Ekker, Stephen, Staff, Nathan, Windebank, Anthony |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6798916/ http://dx.doi.org/10.1017/cts.2017.212 |
Ejemplares similares
-
288 Harnessing the potential of transcriptional adaptation as a mechanism for Amyotrophic lateral sclerosis
por: Gomez, Adriana Morales, et al.
Publicado: (2023) -
3285 Toxicity of Released B Cell Products in Multiple Sclerosis: Effects on Neurons and Oligodendrocytes
por: Zuroff, Leah, et al.
Publicado: (2019) -
4278 Recovery Time is Exaggerated in Individuals with Degenerative Cervical Myelopathy Following Standing Lateral Waist Pulls
por: Boerger, Timothy, et al.
Publicado: (2020) -
4511 Bio-Compatible Implantable Oxygen Sensor Technology with Real-Time Monitoring of Surgical Flaps and Reimplantation
por: Patel, Preet, et al.
Publicado: (2020) -
Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS
por: Goyal, Namita A., et al.
Publicado: (2020)